Department of Oncogenetics, Centre Jean Perrin, CBRV, 63001 Clermont-Ferrand, France.
INSERM U 1240 Molecular Imagery and Theranostic Strategies (IMoST), 63005 Clermont-Ferrand, France.
Int J Mol Sci. 2021 Jan 19;22(2):968. doi: 10.3390/ijms22020968.
Cancer is a major cause of death worldwide. Epigenetic changes in response to external (diet, sports activities, etc.) and internal events are increasingly implicated in tumor initiation and progression. In this review, we focused on post-translational changes in histones and, more particularly, the tri methylation of lysine from histone 3 (H3K27me3) mark, a repressive epigenetic mark often under- or overexpressed in a wide range of cancers. Two actors regulate H3K27 methylation: Jumonji Domain-Containing Protein 3 demethylase (JMJD3) and Enhancer of zeste homolog 2 (EZH2) methyltransferase. A number of studies have highlighted the deregulation of these actors, which is why this scientific review will focus on the role of JMJD3 and, consequently, H3K27me3 in cancer development. Data on JMJD3's involvement in cancer are classified by cancer type: nervous system, prostate, blood, colorectal, breast, lung, liver, ovarian, and gastric cancers.
癌症是全球主要的死亡原因之一。对外界（饮食、体育活动等）和内部事件的表观遗传变化越来越多地涉及肿瘤的发生和发展。在这篇综述中，我们重点关注组蛋白的翻译后变化，特别是组蛋白 3 赖氨酸的三甲基化（H3K27me3）标记，这是一种抑制性的表观遗传标记，在广泛的癌症中常常表达不足或过度表达。有两个因素调节 H3K27 甲基化：Jumonji 结构域包含蛋白 3 去甲基酶（JMJD3）和增强子的外显子 2（EZH2）甲基转移酶。许多研究强调了这些因子的失调，这就是为什么本科学综述将重点介绍 JMJD3 及其随后的 H3K27me3 在癌症发展中的作用。关于 JMJD3 参与癌症的数据按癌症类型分类：神经系统、前列腺、血液、结直肠、乳腺、肺、肝、卵巢和胃癌。
